Measurement of .beta.-emitting nuclides using Cerenkov radiation

Ross, Howard B.

doi:10.1021/ac60279a011

Cited by 148 publications

(69 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, each positron slows down and loses kinetic energy as it travels, producing fewer photons per millimetre than predicted, and will eventually fall below the Cerenkov threshold at some point before it stops. So, we would expect considerably less than this upper bound of 34 detectable visible light photons emitted per positron [17].…”

Section: Cerenkov Radiation For Molecular Imaging: Theory and Simulatmentioning

confidence: 88%

“…For an endpoint positron from 18 F, with an energy of 633 keV, we would therefore expect approximately 16 photons to be produced per millimetre of distance travelled. The range in water of a 633 keV positron is 2.1 mm [17]; thus an upper bound on the number of Cerenkov photons produced by an 18 F positron in the wavelength range 400-800 nm is 34 (16 photons per millimetre, and a distance of 2.1 mm).…”

Section: Cerenkov Radiation For Molecular Imaging: Theory and Simulatmentioning

confidence: 99%

See 1 more Smart Citation

In vivo Cerenkov luminescence imaging: a new tool for molecular imaging

Mitchell

Gill

Boucher

et al. 2011

Phil. Trans. R. Soc. A.

152

189

View full text Add to dashboard Cite

Cerenkov radiation is a phenomenon where optical photons are emitted when a charged particle moves faster than the speed of light for the medium in which it travels. Recently, we and others have discovered that measurable visible light due to the Cerenkov effect is produced in vivo following the administration of b-emitting radionuclides to small animals. Furthermore, the amounts of injected activity required to produce a detectable signal are consistent with small-animal molecular imaging applications. This surprising observation has led to the development of a new hybrid molecular imaging modality known as Cerenkov luminescence imaging (CLI), which allows the spatial distribution of biomolecules labelled with b-emitting radionuclides to be imaged in vivo using sensitive charge-coupled device cameras. We review the physics of Cerenkov radiation as it relates to molecular imaging, present simulation results for light intensity and spatial distribution, and show an example of CLI in a mouse cancer model. CLI allows many common radiotracers to be imaged in widely available in vivo optical imaging systems, and, more importantly, provides a pathway for directly imaging b − -emitting radionuclides that are being developed for therapeutic applications in cancer and that are not readily imaged by existing methods.

show abstract

Section: Cerenkov Radiation For Molecular Imaging: Theory and Simulatmentioning

confidence: 88%

Section: Cerenkov Radiation For Molecular Imaging: Theory and Simulatmentioning

confidence: 99%

In vivo Cerenkov luminescence imaging: a new tool for molecular imaging

Mitchell

Gill

Boucher

et al. 2011

Phil. Trans. R. Soc. A.

152

189

View full text Add to dashboard Cite

show abstract

“…Ilya Frank and Igor Tamm first calculated the number of photons produced by CR, and later Ross published a table of numerically integrated solutions using the Frank-Tamm equations (8). Robertson et al recently used this table to estimate that a 635-keV positron would produce approximately 20 photons, with wavelengths ranging from 250 to 600 nm, and one 18 F decay would produce about 3 photons in average in water (9).…”

Section: Physics Of Crmentioning

confidence: 99%

Harnessing the Power of Radionuclides for Optical Imaging: Cerenkov Luminescence Imaging

Xu¹,

Liu²,

Cheng³

2011

J Nucl Med

132

178

View full text Add to dashboard Cite

Over the past several years, nuclear imaging modalities such as PET and SPECT have received much attention because they have been instrumental not only in preclinical cancer research but also in nuclear medicine. Yet nuclear imaging is limited by high instrumentation cost and subsequently low availability to basic researchers. Cerenkov radiation, a relativistic physical phenomenon that was discovered 70 years ago, has recently become an intriguing subject of study in molecular imaging because of its potential in augmenting nuclear imaging, particularly in preclinical small-animal studies. The intrinsic capability of radionuclides emitting luminescent light from decay is promising because of the possibility of bridging nuclear imaging with optical imaging-a modality that is much less expensive, is easier to use, and has higher throughput than its nuclear counterpart. Thus, with the maturation of this novel imaging technology using Cerenkov radiation, which is termed Cerenkov luminescence imaging, it is foreseeable that advances in both nuclear imaging and preclinical research involving radioisotopes will be significantly accelerated in the near future.

show abstract

“…Moreover, there is increasing interest in the role of medical imaging for both clinical and preclinical research and biomarker qualification (3)(4)(5)(6). Among the imaging technologies, PET with the glucose analog 18 F-FDG is perhaps the most widely used exploratory imaging biomarker in oncology research and clinical trials (7,8). 18 F-FDG exploits the well-known dependence of tumors on glucose metabolism as the primary source of energy (9)(10)(11)(12).…”

mentioning

confidence: 99%

“…Among the imaging technologies, PET with the glucose analog 18 F-FDG is perhaps the most widely used exploratory imaging biomarker in oncology research and clinical trials (7,8). 18 F-FDG exploits the well-known dependence of tumors on glucose metabolism as the primary source of energy (9)(10)(11)(12). To facilitate the translation of imaging biomarkers from research to development, many preclinical imaging facilities use a multimodal approach, wherein the strengths of each individual modality can be combined and leveraged for the development of robust assays (13,14).…”

mentioning

confidence: 99%

Multimodal Imaging with ¹⁸F-FDG PET and Cerenkov Luminescence Imaging After MLN4924 Treatment in a Human Lymphoma Xenograft Model

Robertson¹,

Germanos²,

Manfredi³

et al. 2011

J Nucl Med

View full text Add to dashboard Cite

Cerenkov luminescence imaging (CLI) is an emerging imaging technique that combines aspects of both optical and nuclear imaging fields. The ability to fully evaluate the correlation and sensitivity of CLI to PET is critical to progress this technique further for use in high-throughput screening of pharmaceutical compounds. To achieve this milestone, it must first be established that CLI data correlate to PET data in an in vivo preclinical antitumor study. We used MLN4924, a phase 2 oncology therapeutic, which targets and inhibits the NEDD8-activating enzyme pathway involved in the ubiquitin-proteasome system. We compared the efficacious effects of MLN4924 using PET and Cerenkov luminescence image values in the same animals. Methods: Imaging of 18 F-FDG uptake was performed at 5 time points after drug treatment in the subcutaneously implanted diffuse large B-cell lymphoma tumor line OCI-Ly10. Data were acquired with both modalities on the same day, with a 15-min delay between CLI and PET. PET data analysis was performed using percentage injected dose per cubic centimeter of tissue (%ID/cm 3 ), average standardized uptake values, and total glycolytic volume. CLI measurements were radiance, radiance per injected dose (radiance/ID), and total radiant volume. Results: A strong correlation was found between PET total glycolytic volume and CLI total radiant volume (r 2 5 0.99) and various PET and CLI analysis methods, with strong correlations found between PET %ID/cm 3 and CLI radiance (r 2 5 0.83) and CLI radiance/ID (r 2 5 0.82). MLN4924 demonstrated a significant reduction in tumor volume after treatment (volume ratio of treated vs. control, 0.114 at day 29). Conclusion: The PET and CLI data presented confirm the correlation and dynamic sensitivity of this new imaging modality. CLI provides a preclinical alternative to expensive PET instrumentation. Future highthroughput studies should provide for quicker turnaround and higher cost-to-return benefits in the drug discovery process.

show abstract

Measurement of .beta.-emitting nuclides using Cerenkov radiation

Cited by 148 publications

References 4 publications

In vivo Cerenkov luminescence imaging: a new tool for molecular imaging

In vivo Cerenkov luminescence imaging: a new tool for molecular imaging

Harnessing the Power of Radionuclides for Optical Imaging: Cerenkov Luminescence Imaging

Multimodal Imaging with ¹⁸F-FDG PET and Cerenkov Luminescence Imaging After MLN4924 Treatment in a Human Lymphoma Xenograft Model

Contact Info

Product

Resources

About

Measurement of .beta.-emitting nuclides using Cerenkov radiation

Cited by 148 publications

References 4 publications

In vivo Cerenkov luminescence imaging: a new tool for molecular imaging

In vivo Cerenkov luminescence imaging: a new tool for molecular imaging

Harnessing the Power of Radionuclides for Optical Imaging: Cerenkov Luminescence Imaging

Multimodal Imaging with 18F-FDG PET and Cerenkov Luminescence Imaging After MLN4924 Treatment in a Human Lymphoma Xenograft Model

Contact Info

Product

Resources

About

Multimodal Imaging with ¹⁸F-FDG PET and Cerenkov Luminescence Imaging After MLN4924 Treatment in a Human Lymphoma Xenograft Model